1. Home
  2. VTYX vs AXG Comparison

VTYX vs AXG Comparison

Compare VTYX & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.17

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

AXG

Solowin Holdings Class A Ordinary Share

N/A

Current Price

$3.46

Market Cap

585.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VTYX
AXG
Founded
2018
2021
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
713.6M
585.9M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
VTYX
AXG
Price
$8.17
$3.46
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$14.60
N/A
AVG Volume (30 Days)
1.7M
766.1K
Earning Date
11-06-2025
06-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,316,000.00
Revenue This Year
N/A
$28.53
Revenue Next Year
N/A
$54.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$1.16
52 Week High
$10.55
$5.09

Technical Indicators

Market Signals
Indicator
VTYX
AXG
Relative Strength Index (RSI) 47.12 N/A
Support Level $8.39 N/A
Resistance Level $9.13 N/A
Average True Range (ATR) 0.63 0.00
MACD -0.25 0.00
Stochastic Oscillator 20.35 0.00

Price Performance

Historical Comparison
VTYX
AXG

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About AXG Solowin Holdings Class A Ordinary Share

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.

Share on Social Networks: